A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Obesity or Overweight, and Type 2 Diabetes

What this Trial Is About

Researchers are evaluating the efficacy and safety of eloralintide compared with placebo for reducing body weight in adults with overweight or obesity who also have type 2 diabetes. This Phase 3 study is designed as a randomized, double-blind, placebo-controlled trial sponsored by Eli Lilly and Company. The study aims to understand how well eloralintide works for weight loss and its effects on related health measures over a period of about 75 weeks. Participants will be randomly assigned to receive one of four doses of eloralintide or a placebo, all given as weekly subcutaneous injections. The treatment period lasts 64 weeks, during which participants will receive their assigned dose once weekly. The study compares different doses of eloralintide to placebo to assess its impact on body weight and other health outcomes. During the study, participants will undergo regular assessments including body weight, body fat, waist circumference, blood sugar control HbA1c, blood pressure, and various blood markers like triglycerides and insulin. Patient questionnaires will measure physical function and quality of life. Researchers will also monitor medication use and pharmacokinetics of eloralintide. Participation involves about 75 weeks including follow-up, with close monitoring for safety and treatment effects.

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes